Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Dried Blood Used to Screen Newborns for Severe Immunodeficiency

By LabMedica International staff writers
Posted on 25 Aug 2010
A molecular test on dried blood spots is very sensitive for diagnosing severe combined immunodeficiency (SCID) in newborns.

The assay employs a quantitative polymerase chain reaction (PCR) for T-cell receptor excision circles (TREC), which are copies of DNA produced only by T-cells. More...
If the calculated TREC count is less than 30 copies/μL, it is associated with 100% sensitivity and 97% specificity for identifying SCID.

Severe combined immunodeficiency (SCID) represents a group of rare, sometimes fatal, congenital disorders characterized by little or no immune response. The defining feature of SCID, commonly known as "bubble boy" disease, is a defect in the specialized white blood cells (B- and T-lymphocytes). A review of the various methods used to diagnose SCID was published in the May 2010 issue of Pediatrics.

The review noted that a second blood spot study evaluated a two-tiered approach in which interleukin IL-7 was measured first using an enzyme-linked immunosorbent assay (ELISA), and then TRECs from those with elevated IL-7 levels, which occurs in the absence of T-cells. This study included samples from 13 children with SCID and 183 anonymized dried blood spots. For the first tier (IL-7 measurement) they calculated 96.1% specificity and 85% sensitivity (confidence interval: 55%–98%); for the second tier (TREC count) they calculated a specificity of 92.3% and a sensitivity that "approaches 100%.” If the more stringent standard of undetectable TRECs is used as a positive test result, they calculated a false-positive rate of 1.5% among children discharged from routine nurseries and 5% among children from special-care nurseries.

The study reported that on whole blood samples from infants with a median age of four months, lymphocyte counts that were less than 2.8 x 109/L had a sensitivity of 86% and a specificity of 94% for detecting SCID. From another study, they determined that among infants with a median age of 84 days, lymphocyte counts that were less than 5,000/μL had a sensitivity of only 56%, but a specificity of 100%, for detecting SCID.

Ellen A. Lipstein, M.D., M.P.H. of the MassGeneral Hospital for Children, (Boston, MA, USA), said, "The development of methods to screen for SCID by using dried blood spots, in contrast to using lymphocyte counts, which require whole blood, improves the feasibility of instituting SCID screening within current programs."

Related Links:
MassGeneral Hospital for Children




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.